- Home
- OTLK vs DXR Comparison
OTLK vs DXR Comparison
Compare OTLK & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | DXR |
|---|---|---|
| Founded | 2010 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.8M | 66.3M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | DXR |
|---|---|---|
| Price | $2.06 | $12.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $5.25 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 5.5M | 4.3K |
| Earning Date | 12-26-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $1,505,322.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $342.80 | N/A |
| P/E Ratio | ★ N/A | $35.63 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.79 | $6.55 |
| 52 Week High | $3.39 | $14.15 |
Technical Indicators
Market Signals| Indicator | OTLK | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 69.44 | 48.48 |
| Support Level | $1.51 | $12.65 |
| Resistance Level | $2.10 | $13.02 |
| Average True Range (ATR) | 0.20 | 0.45 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 93.22 | 32.94 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.